Research Topics
| Martin LambertSummaryAffiliation: University of Hamburg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disordersMartin Lambert
Department for Psychiatry and Psychotherapy, University of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
Int Clin Psychopharmacol 18:251-60. 2003..The results underline the need of Phase IV studies for the assessment of clinical antipsychotic efficacy and tolerability...- Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherenceM Lambert
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University of Hamburg, Martini Street 52, 20246 Hamburg, Germany
Eur Psychiatry 19:415-22. 2004.... - Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes studyM Lambert
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
Acta Psychiatr Scand 111:232-43. 2005..The European Schizophrenia Out-patient Health Outcomes study is an observational study investigating treatment in schizophrenia. We report treatment-emergent adverse events during the first 6 months of treatment... - The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosisM Lambert
Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre PEDIC, University Hospital Hamburg Eppendorf, Hamburg, Germany
Acta Psychiatr Scand 112:141-8. 2005..The main aim of the present study was to assess the impact of baseline SUD and course of SUD on remission of positive symptoms... - Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record studyM Lambert
Department of Psychiatry and Psychotherapy, University of Hamburg, Martini Street 52, 20246 Hamburg, Germany
Pharmacopsychiatry 38:206-13. 2005..Previous studies comparing olanzapine (OLZ) and risperidone (RIS) have tended to focus on multiple-episode patients, with no studies examining their comparative efficacy in a non-selective sample of first-episode psychosis... - Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 yearsMartin Lambert
Psychosis Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Germany
Schizophr Res 107:165-72. 2009.... - Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorderM Lambert
Psychosis Early Detection and Intervention Centre PEDIC, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Centre, Hamburg Eppendorf, Germany
Pharmacopsychiatry 41:182-9. 2008..Agitation is a common phenomenon in schizophrenia or acute mania. Because of the inability of patients to give informed consent in such situations, data from consenting studies are limited... - Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophreniaM Lambert
Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Acta Psychiatr Scand 118:220-9. 2008..Few studies have prospectively examined remission and recovery as well as their predictors in schizophrenia simultaneously. Aims of the study were to identify remission and recovery rates as well as their predictors in schizophrenia... - Management of incomplete remission and treatment resistance in first-episode psychosisMartin Lambert
University Medical Centre Hamburg Eppendorf, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Martinistreet 52, D 20246 Hamburg, Germany
Expert Opin Pharmacother 9:2039-51. 2008..Incomplete remission and treatment resistance are common even in first-episode psychosis patients... - Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophreniaMartin Lambert
Psychosis Early Detection and Intervention Centre PEDIC, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
J Clin Psychiatry 67:1690-7. 2006.... - Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulprideM Lambert
Psychosis Early Detection and Intervention Centre PEDIC, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy of the University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
Acta Psychiatr Scand 115:106-13. 2007..Studies of subjective wellbeing (SW) in schizophrenia have missed to define and to assess rate and predictors of SW response (SW-res) and SW remission (SW-rem)... - Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of lifeMartin Lambert
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Germany
CNS Drugs 18:5-17; discussion 41-3. 2004..Ideally, an atypical drug which is known not to have a negative effect on attention, affect or motivation should be chosen... - Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial)Martin Lambert
Psychosis Centre, Department for Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
J Clin Psychiatry 71:1313-23. 2010.... - [Conversion from typical to atypical neuroleptics. Guidelines for ambulatory and inpatient treatment]M Lambert
Klinik für Psychiatrie und Psychotherapie der Universität Hamburg
Nervenarzt 71:859-75. 2000..The present article addresses guidelines for the conversion from conventional to atypical neuroleptics in inpatient and outpatient settings... - Pharmacotherapy of first-episode psychosisMartin Lambert
Centre for Psychosocial Medicine, Clinic for Psychiatry and Psychotherapy of the University of Hamburg, Martinistreet 52, 20246 Hamburg, Germany
Expert Opin Pharmacother 4:717-50. 2003.... - Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulprideM Lambert
Psychosis Early Detection and Intervention Centre PEDIC, Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf
Pharmacopsychiatry 42:277-83. 2009..Limiting factors of these studies include the restriction on symptomatic outcome, the inclusion of mostly moderately ill patients, and the use of various antipsychotics... - Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years laterMartin Lambert
Psychosis Centre, Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg Eppendorf, German
Dialogues Clin Neurosci 12:393-407. 2010..Future research should therefore search for criteria of these dimensions and test whether the RSWG remission criteria consistently predict a "good" outcome with respect to functioning and quality of life... - Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevanceM Lambert
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Germany
Pharmacopsychiatry 36:S181-90. 2003..This article reviews existing literature in order to approach relevant questions for pharmacotherapy... - Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patientsChristian G Huber
Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Centre Hamburg Eppendorf, Germany
Schizophr Res 100:342-8. 2008..Clinical management of aggression depends on the availability of easily administrable measurements allowing reliable evaluation. The present study's aim is to validate a Clinical Global Impression-Severity of Aggression scale (CGI-A)... - Subjective wellbeing under quetiapine treatment: effect of diagnosis, mood state, and anxietyMartin Lambert
Psychosis Early Detection and Intervention Centre PEDIC, Centre for Psychosocial Medicine, Department of Psychiatry, University Medical Center Hamburg Eppendorf, Germany
Schizophr Res 110:72-9. 2009..To examine the effect of diagnosis, mood state, and anxiety on subjective wellbeing in patients with affective and non-affective psychotic disorders treated with quetiapine IR... - Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural modelsMartin Lambert
Psychosis Centre, Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Centre Hamburg Eppendorf, Germany
J Clin Psychopharmacol 31:226-30. 2011..This study examined the differential effects of first- (FGAs) versus second-generation antipsychotics (SGAs) on subjective well-being in patients with schizophrenia... - Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophreniaAnne Karow
Center for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
J Clin Psychiatry 68:75-80. 2007.... - Diagnostic stability 18 months after treatment initiation for first-episode psychosisBenno G Schimmelmann
Centre for Psychosocial Medicine, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
J Clin Psychiatry 66:1239-46. 2005..2) Comparison between those patients who shifted from DSM-IV schizophreniform disorder to schizophrenia or schizo-affective disorder and those whose diagnosis of schizophreniform disorder remained stable... - Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosisMartin Lambert
Psychosis Early Detection and Intervention Centre, Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany
J Clin Psychopharmacol 30:565-72. 2010..The present study aims to assess the prevalence and predictors of such a "medication refusal" subgroup and its association with illness outcome... - The impact of subjective well-being under neuroleptic treatment on compliance and remissionWalter de Millas
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Dialogues Clin Neurosci 8:131-6. 2006..The data strongly suggest that a systematic evaluation of the patient's perspective of antipsychotic treatment is meaningful and necessary to increase compliance, functional outcome, and long-term prognosis... - Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictorsChristian G Huber
University Medical Centre Hamburg Eppendorf, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Martinistreet 52, D 20246 Hamburg, Germany
Expert Opin Pharmacother 9:2027-38. 2008..Different definitions for these terms have been used in psychiatric research, making generalized statements about the prevalence and predictors of treatment resistance difficult... - Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trialDuerten Kudla
Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
Eur Psychiatry 22:195-202. 2007..Secondary objectives included quality of life, subjective well-being, tolerability, and safety... - Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatmentM Lambert
Psychosis Centre, Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf Hamburg, Martinistreet 52, 20246 Hamburg, Germany
Eur Psychiatry 25:220-9. 2010..To measure symptomatic and functional remission in patients treated with risperidone long-acting injectable (RLAI)... - The CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansDieter Naber
Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany
CNS Drugs 23:649-59. 2009..There is no single antipsychotic that is best for every schizophrenia patient, as individual responses differ markedly. For successfully individualized treatment, a multitude of antipsychotic options are needed... - Comorbidity of schizophrenia and galactosemia: effective clozapine treatment with weight gainChristian Haasen
Department of Psychiary and Psychotherapy, University Hospital Eppendorf, Hamburg, Germany
Int Clin Psychopharmacol 18:113-5. 2003.... - Subjective cognitive dysfunction in first-episode and chronic schizophrenic patientsS Moritz
Clinic for Psychiatry and Psychotherapy, University Clinic Hamburg-Eppendorf, Hamburg, Germany
Compr Psychiatry 42:213-6. 2001..In marked contrast to a Kraepelinian view of schizophrenia, the present data confirm previous studies conducted with objective neuropsychological tests that schizophrenia is a neurodevelopmental rather than a neurodegenerative disorder... - Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (access trial)Anne Karow
Psychosis Centre, Department for Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
J Clin Psychiatry 73:e402-8. 2012..ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system... - Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanismDieter Naber
Department of Psychiatry and Psychotherapy, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, Hamburg 20246, Germany
Prog Neuropsychopharmacol Biol Psychiatry 28:1213-9. 2004..However, only post-marketing experience will show whether the positive results of these controlled trials can be replicated in everyday practice... - [Sexual problems in patients with schizophrenia]Daniel Schottle
Psychosen Ersterkennungs und Behandlungsprojekt PEB, Zentrum fur Psychosoziale Medizin, Klinik fur Psychiatrie und Psychotherapie, Universitatsklinikum Hamburg Eppendorf
Psychiatr Prax 36:160-8. 2009..Overview on the current knowledge concerning sexual dysfunctions in patients with schizophrenia and implications for treatment, compliance, quality of life and partnership... - Under what circumstances do patients with schizophrenia jump to conclusions? A liberal acceptance accountSteffen Moritz
Universitatsklinikum Hamburg Eppendorf, Klinik fur Psychiatrie und Psychotherapie, Germany
Br J Clin Psychol 46:127-37. 2007..We have recently proposed a liberal acceptance (LA) bias to account for decision-making biases in schizophrenia, which claims that under heightened ambiguity the jump to conclusions (JTC) bias is abolished in schizophrenia... - [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease]Dieter Naber
Universitatsklinikum Hamburg Eppendorf, Klinik fur Psychiatrie und Psychotherapie
Psychiatr Prax 31:S230-2. 2004.... - Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugsD Naber
Universitäts Krankenhaus Hamburg Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistrasse 52, 20246 Hamburg, Germany
Schizophr Res 50:79-88. 2001..It is concluded that the assessment of subjective well-being under antipsychotic treatment provides an independent outcome measure which is relevant to compliance... - Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophreniaD Naber
Department of Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Germany
Acta Psychiatr Scand 111:106-15. 2005..This randomized double-blind multicenter trial evaluated the effects of olanzapine vs. clozapine on subjective well-being, quality of life (QOL) and clinical outcome... - PANSS syndromes and quality of life in schizophreniaA Karow
Department of Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
Psychopathology 38:320-6. 2005..The leading hypotheses were: (1) affective symptoms, especially depression and anxiety, are mostly associated with QOL longitudinally and (2) in the acute phase, QOL is also associated with positive schizophrenia symptoms... - Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenicsS Moritz
Universitäts Krankenhaus Hamburg Eppendorf, Klinik fur Psychiatrie und Psychotherapie, Hamburg, Deutschland
Psychopathology 33:48-51. 2000..005). It is suggested that the exploration and treatment of neuropsychological deficits in schizophrenia is of great clinical importance with regard to its impact on both functional and symptomatic outcome in schizophrenia... - [Atypical antipsychotics in therapy refractory schizophrenia]I Schafer
Klinik für Psychiatrie und Psychoterapie der Universitätsklinik Hamburg Eppendorf
Nervenarzt 75:79-91. 2004..Case studies also indicate the efficacy of combining different atypical antipsychotics, but no systematic research on this issue has been done so far... - [The initial dysphoric reaction (IDR) to the first dose of neuroleptics]B Graf Schimmelmann
Klinik fur Kinder und Jugendpsychiatrie und psychotherapie, Universitatsklinikum Hamburg Eppendorf, Hamburg
Nervenarzt 75:36-43. 2004..Further research should include placebo-controlled studies and the evaluation of specific pretreatment variables. To assess the aetiology of IDR, further basic research is needed... - Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neurolepticsS Moritz
Universitäts Krankenhaus Hamburg Eppendorf, Klinik fur Psychiatrie und Psychotherapie, Martinistrasse 52, D 20246, Hamburg, Germany
Eur Psychiatry 16:354-61. 2001..Previous findings reporting correlations between negative symptomatology and neurocognition may have been confounded by the adverse consequences of typical neuroleptics... - Brief Psychiatric Rating Scale - Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosisChristian G Huber
Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Centre Hamburg Eppendorf, Martinistr 52, D 20246 Hamburg, Germany
Schizophr Res 134:273-8. 2012..Although there are studies on prevalence and clinical predictors of these conditions, little is known on the influence of psychopathology and neuropsychological dysfunction... - Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapineStefan Bender
Department of Psychiatry and Psychotherapy, University of Duisburg Essen, Germany
Int J Neuropsychopharmacol 9:135-45. 2006..However, Stroop reaction time improved with olanzapine while clozapine had a stronger effect on improving negative symptoms, thus suggestive of a differential drug effect... - Schneiderian first rank symptoms predict poor outcome within first episode manic psychosisPhilippe Conus
ORYGEN Research Centre, Parkville, Victoria, Australia
J Affect Disord 81:259-68. 2004..While some authors have found a correlation between such symptoms and outcome, their predictive value was rather limited in these studies... - Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychoticsBenno Graf Schimmelmann
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg Essen, Essen, Germany
J Child Adolesc Psychopharmacol 15:249-58. 2005..The aim of this pilot study was to evaluate the subjective distress-related to different SE and its association with subjective well-being in a sample of adolescents treated with atypical antipsychotics... - Manifestation of multiple sclerosis with paranoid-hallucinatory psychosisJens Reimer
J Neurol 253:531-2. 2006 - Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophreniaPeter M Wehmeier
Medical Department, Child and Adolescent Psychiatry, Lilly Deutschland, Saalburgstr 153, 61350 Bad Homburg, Germany
J Psychiatr Res 42:676-83. 2008..These findings suggest that various factors may predict whether a patient with schizophrenia experiences a continuously high QoL, a continuously moderate QoL, a continuously low QoL, or improving QoL whilst on antipsychotic treatment... - Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohortBenno G Schimmelmann
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg Essen, Virchowstrasse 174, 45147 Essen, Germany
J Psychiatr Res 42:982-90. 2008..To assess the impact of duration of untreated psychosis (DUP) on baseline and 18-month follow-up characteristics controlling for relevant confounders in an epidemiological first-episode psychosis (FEP) cohort... - Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO studyDiego Novick
Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
Psychopharmacology (Berl) 191:1015-22. 2007..Symptomatic remission is an achievable goal of treatment in patients with schizophrenia... - A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disordersBenno Graf Schimmelmann
Department of Child and Adolescent Psychiatry, University of Duisburg Essen, Virchowstrasse 174, 45147 Essen, Germany
J Child Adolesc Psychopharmacol 17:768-78. 2007..The aim of this study was to investigate the effectiveness, tolerability, and safety of quetiapine in adolescents with schizophrenia, schizophreniform, and schizoaffective disorders in a prospective open-label study... - Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patientsBenno G Schimmelmann
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg Essen, Virchowstr 174, 45147 Essen, Germany
Schizophr Res 95:1-8. 2007..To assess pre-treatment, baseline, and outcome differences of patients with early- (onset<age 18) and adult-onset (onset>or=age 18) psychosis in an epidemiological cohort of first-episode patients... - Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy studyStephen J Wood
Melbourne Neuropsychiatry Centre, University of Melbourne, c o National Neuroscience Facility, 161 Barry Street, Carlton, Melbourne, Victoria 3053, Australia
Arch Gen Psychiatry 63:969-76. 2006..These studies have generally been negative, perhaps because gray and white matter volumes inaccurately assess the underlying dysfunction that might be predictive of outcome... - Predictors of service disengagement in first-admitted adolescents with psychosisBenno Graf Schimmelmann
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg Essen, Germany
J Am Acad Child Adolesc Psychiatry 45:990-9. 2006..To assess the risk and predictors of service disengagement in adolescents with first-episode psychosis (FEP) receiving their first treatment in a long-standing early intervention and prevention centre... - Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area samplePhilippe Conus
Département Universitaire de Psychiatrie CHUV, Universite de Lausanne, Prilly, Switzerland
Bipolar Disord 8:221-31. 2006..Such studies have been conducted in selected samples with restrictive measures of outcome. We aimed to explore outcome and its predictors in a catchment area sample of first-episode psychotic mania of DSM-III-R bipolar I disorder... - Familial psychopathology in the First Episode Psychosis Outcome StudyKatherine I Morley
ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Victoria, Australia
Aust N Z J Psychiatry 42:617-26. 2008.... - Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challengesW Wolfgang Fleischhacker
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
J Clin Psychiatry 69:514-9. 2008....